John Rogowskyj is a scientist in the Precision Genomics group, which seeks to identify clinically relevant gene-editing targets. His previous work includes drug discovery and high-throughput screening at the Baruch Blumberg Institute, focusing on Hepatitis B and Liver cancer. John has experience working with in vivo virology and immunology models, ranging from ectromelia to Graft-Versus-Host Disease (GVHD) at The Pennsylvania State College of Medicine and Incyte, respectively. Working with Siemens Healthineers, he helped implement regulatory stadards for clinical in-vitro diagnostics and characterize new and updated clinical assays in accordance with current best practices and regulatory requirements. His favorite things about working at the Gene Editing Institute are phenotye-driven therapeutic discovery, and investigating combination therapies.
